STAT reports that a much-anticipated AI technology designed to accelerate drug discovery has not met expectations. The article points to another instance where the promise of AI-led breakthroughs in heart drug development did not materialise.
This outcome matters for pharma and biotech leaders who face growing pressure to adopt new technologies while managing risk and regulatory scrutiny. The case serves as a reminder to scrutinise AI claims and ensure robust validation before committing resources or altering research strategies.
